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Abstract
Tuberculosis is a leading killer of young adults worldwide and the global scourge of multi-drug
resistant tuberculosis is reaching epidemic proportions. It is endemic in most developing countries
and resurgent in developed and developing countries with high rates of human immunodeficiency
virus infection. This article reviews the current situation in terms of drug delivery approaches for
tuberculosis chemotherapy. A number of novel implant-, microparticulate-, and various other
carrier-based drug delivery systems incorporating the principal anti-tuberculosis agents have been
fabricated that either target the site of tuberculosis infection or reduce the dosing frequency with
the aim of improving patient outcomes. These developments in drug delivery represent attractive
options with significant merit, however, there is a requisite to manufacture an oral system, which
directly addresses issues of unacceptable rifampicin bioavailability in fixed-dose combinations. This
is fostered by the need to deliver medications to patients more efficiently and with fewer side
effects, especially in developing countries. The fabrication of a polymeric once-daily oral
multiparticulate fixed-dose combination of the principal anti-tuberculosis drugs, which attains
segregated delivery of rifampicin and isoniazid for improved rifampicin bioavailability, could be a
step in the right direction in addressing issues of treatment failure due to patient non-compliance.
Background
Tuberculosis (TB), a ubiquitous, highly contagious
chronic granulomatous bacterial infection, is still a lead-
ing killer of young adults worldwide. TB has returned with
a new face and the global scourge of multi-drug resistant
TB (MDR TB) is reaching epidemic proportions.
Nearly one-third of the global population – two billion
people – is infected with Mycobacterium tuberculosis (M.
tuberculosis), more than eight million people develop
active TB every year, and approximately two million die
annually (World Health Organization, 2003). TB is the
world's second most common cause of death from infec-
tious disease, after acquired immunodefiency syndrome
(AIDS) [1]. It is endemic in most developing countries
and resurgent in developed and developing countries with
high rates of human immunodeficiency virus (HIV) infec-
tion. With particular reference to Africa, the increase in TB
incidence is strongly associated with the prevalence of
HIV infection: rates of HIV infection among TB patients
are correspondingly high, exceeding 60% in South Africa,
Botswana, Zambia, and Zimbabwe [2].
Mortality rates of TB range from 50 to 80% in untreated
smear-positive individuals to 30% with inconsistent con-
trol programmes and drop to lower than 5% when
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directly observed therapy (DOT) and active TB control
programmes are instituted [2].
The TB incidence (number of new cases arising each year)
and mortality in each of the WHO regions is depicted in
Figure 1. The incidence of all forms of TB, the incidence of
infectious cases, and mortality are represented as the rate
per 100 000 population [3]. The majority of cases (5–6
million) are in people aged 15–49 years. The largest
number of cases occurs in the South-East Asia Region,
which accounts for 33% of incident cases globally. How-
ever in 2003, the estimated incidence per capita in sub-
Saharan Africa was nearly twice that of the South-East
Asia, at 290 to 350 cases per 100 000 population [1,3].
M. tuberculosis is a highly contagious, airborne, slow-grow-
ing, Gram-positive aerobic rod-shaped acid-fast bacillus.
The cell wall has high lipid content and allows the bacte-
ria to survive within macrophages. It also provides the
organism with a resistant barrier to many common drugs
[4,5].
Man is the primary host for M. tuberculosis. Infection is
spread via airborne dissemination of aerosolised bacteria-
containing droplet nuclei of 1–5 µm in diameter that carry
M. tuberculosis droplets from an individual with infectious
TB disease to an uninfected individual. The infectious
droplet nuclei are inhaled and lodge in the alveoli in the
distal airways. M tuberculosis is then taken up by alveolar
macrophages, initiating a cascade of events that results in
either successful containment of the infection or progres-
sion to active disease (primary progressive TB). Risk of
development of active disease varies according to time
since infection, age, and host immunity, however, the life-
Estimated TB incidence and mortality in 2003 Figure 1
Estimated TB incidence and mortality in 2003. Data extracted from WHO Tuberculosis data sheet [3].
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time risk of disease for a newly infected young child has
been estimated at 10% [1,6,7]. Schematic representation
of the progression of TB is shown in Figure 2.
This article seeks to review the current situation in terms
of drug delivery approaches for TB chemotherapy. In so
doing, the need for the development of a novel oral sys-
tem that could overcome the bioavailability concerns of
currently available fixed-dose anti-TB drug combinations
in addition to assisting in achieving improved patient
compliance with the existing regimen, will be addressed.
Currect anti-tuberculosis chemotherapy
Since the control measures for TB such as Bacillus Cal-
mette-Guérin (BCG) vaccination and chemoprophylaxis
appear to be unsatisfactory, treatment with anti-tubercu-
lar (anti-TB) drugs becomes the only option available. The
goals of treatment are to ensure cure without relapse, to
prevent death, to impede transmission, and to prevent the
emergence of drug resistance. Long-term treatment with a
combination of drugs is required [8]. Treatment of active
TB with a single drug should never be attempted, and a
single drug should never be added to a failing regimen,
the result being development of MDR TB [9]. As suggested
by WHO [10], treatment of TB and drug resistant cases
requires multi-drug therapy, comprising:
1. An initial intensive phase of rifampicin (RIF), isoniazid
(INH), pyrazinamide (PYZ), and ethambutol (ETB) daily
for 2 months.
2. A continuation phase of RIF and INH for a further 4
months, either daily or 3 times per week, to be adminis-
tered as advised in Table 1.
INH eradicates most of the rapidly replicating bacilli in
the first 2 weeks of treatment, together with streptomycin
and ETB. Thereafter, RIF and PYZ have an important role
in the sterilisation of lesions by eradicating organisms;
these two drugs are crucial for successful 6-month treat-
ment regimens. RIF kills low or non-replicating organisms
and the high sterilising effect of PYZ serves to act on sem-
idormant bacilli not affected by any other anti-TB agents
in sites hostile to the penetration and action of the other
drugs [12,13]. INH and RIF, the two most potent anti-TB
drugs, kill more than 99% of tubercular bacilli within 2
months of initiation of therapy [14,15]. Using these drugs
in conjunction with each other reduces anti-TB therapy
from 18 months to 6 months. The sites of action of these
principle anti-TB agents are schematically illustrated in
Figure 3, as delineated by Rattan et al., Parsons et al., and
Somoskovi et al. [16-18]. The emergence of strains resist-
ant to either of these drugs causes major concern, as treat-
ment is then deferred to drugs that are less effective, have
more toxic side effects, and result in higher death rates,
especially among HIV-infected persons [16]. The current
armamentarium of drugs available for the treatment of
TB, their mechanism of action, and activity, have been
reviewed by numerous authors [4,5,19-40] and appear in
Table 2.
TB is treated with a multi-drug regimen, and is thus excep-
tionally vulnerable to incidences of side effects, unsatis-
factory patient compliance and slow improvement of
patients [41]. Therefore, despite the availability of these
highly effective treatments for TB, cure rates remain low,
as commercial anti-TB formulations are inconvenient to
administer and patients do not take the prescribed medi-
cations with sufficient regularity and duration to achieve
a cure [42]. Patients have to consume a large number of
tablets (up to eight at one time), which is a common cause
for non-compliance. It can be anticipated that non-opti-
mal application of these short course regimens will result
in the deterioration of their therapeutic potential, an esca-
lation in the mortality rate and increased risk of develop-
ing acquired drug resistance [3,43,44]. Resistance of M.
tuberculosis to anti-TB agents is a worldwide problem in
both immunocompetent and HIV-infected populations
[45,46].
Novel drug delivery systems for the treatment of 
TB
Chemotherapy of TB is complicated by the need of multi-
drug regimens that need to be administered over long
Table 1: Regimen 1 – for treatment of new smear positive adult patients
Intensive Phase – 2 months Under 50 kg Over 50 kg
RIF/INH/PYZ/ETB
Combination tablet 120/60/300/200 mg daily, 5 days per week 4 tablets 5 tablets
Continuation phase – 4 months Under 50 kg Over 50 kg
RIF/INH
Combination tablet 150/100 mg 3 tablets
Combination tablet 300/150 mg - 2 tablets
Data extracted from Gibbon [11]Respiratory Research 2006, 7:118 http://respiratory-research.com/content/7/1/118
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Pathogenesis of TB Figure 2
Pathogenesis of TB.
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Sites of action of the principal anti-TB drugs Figure 3
Sites of action of the principal anti-TB drugs. Adapted in part from Rattan et al.; Parsons et al.; Somoskovi et al. 
[16,17,18].
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Table 2: Classes of anti-TB drugs
Agent Mechanism of Action Activity Against M. tubercolosis
First-line agents
Rifampicin (RIF) Inhibits bacterial RNA synthesis by binding to the β subunit of bacterial DNA-dependent RNA-polymerase 
(DDRP) Inhibition of DDRP leads to blocking of the initiation chain formation in RNA synthesis. One of the 
most effective antituberculosis agents available and is bactericidal for intra- and extra-cellular bacteria [4,19].
RIF inhibits susceptible organisms at 
concentrations of less than 1 µg/mL [4].
Isoniazid (INH) Most active drug for the treatment of TB caused by susceptibe strains. Is a pro-drug activated by katG, which 
exerts its lethal effect through inhibition of synthesis of mycolic acids, an essential component of 
mycobacterial cell walls, through formation of a covalent complex with an acyl carrier protein (AcpM) and 
KasA, a beta-ktoacyl carrier protein synthetase [4,5]
INH inhibits tubercle bacilli at a concentration 
of 0.2 µg/mL [4].
Pyrazinamide (PYZ) Converted to the active pyrazanoic acid (encoded by pncA) by pyrazinamidase in susceptible organisms. 
Pyrazanoic acid lowers pH in the immediate surroundings of M. tuberculosis – organism is unable to grow. 
May also function as an antimetabolite of nicotinamide and interfere with the synthesis of NAD, inhibiting 
the synthesis of short-chain, fatty-acid precursors [4,5]
Inhibits M. tuberculosis and other mycobacteria 
at concentrations of 20 µg/mL [4].
Ethambutol (ETB) Inhibits mycobacterial arabinosyl transferases (encoded by the embCAB operon) involved in the 
polymerization of D-arabinofuranose to arabinoglycan, an essential cell wall component [4,5].
Ethambutol is generally bacteriostatic, but at 
high doses (25 mg/kg) can be bactericidal [20]. 
Inhibits susceptible strains of M. tuberculosis at 
concentrations of 1–5 µg/mL [4].
Aminoglycosides (injectable)
Streptomycin, kanamycin, 
amikacin, capreomycin
The aminoglycosides are irreversible inhibitors of protein synthesis through binding to specific 30S-subunit 
ribosomal proteins [4].
Bactericidal. In vitro and in vivo clinical data 
support use [21,22,23].
Fluoroquinolones
Ciprofloxacin, ofloxacin, 
levofloxacin, moxifloxacin, 
gatifloxacin, sparfloxacin
Inhibit bacterial DNA synthesis through inhibition of bacterial topoisomerase II (DNA gyrase) and 
topoisomerase IV, which are responsible for the relaxation of supercoiled DNA and the separation of 
replicated chromosomal DNA, respectively [4].
Bactericidal, broad spectrum antibacterials [5]. 
In-vitro and in-vivo clinical data support use 
[24,25]. Ciprofloxacin and levofloxacin inhibit 
strains of M. tuberculosis at concentrations of 
less than 2 µg/ml. Newer agents (moxifloxacin, 
gatifloxacin, sparfloxacin) have lower minimum 
inhibitory concentrations [4,26,27].
Bacteriostatic second-line 
drugs
Ethionamide Chemically related to INH, converted via oxidation to ethionamide sulfoxide, blocks the synthesis of mycolic 
acids [4,5].
Inhibits most tubercle bacilli at concentrations 
of 2.5 µg/mL or less [4].
Cycloserine Structural analogue of D-alanine, inhibits incorporation of D-alanine into peptidoglycan pentapeptide 
through inhibition of alanine racemase [4].
Inhibits strains of M. tuberculosis at 
concentratins of 15–20 µg/mL [4].
P-aminosalicylic acid Anti-metabolite interfering with incorporation of para-aminobenzoic acid into folic acid – folate synthesis 
antagonist [4,5].
Inhibits tubercle bacilli at concentrations of 1–
5 µg/mL [4].R
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Other drugs Potentially useful agents with conflicting animal or clinical evidence or agents with unclear efficacy because of 
possible cross-resistance.
Clofazimine Unknown, but may involve DNA binding [4]. Possesses direct antimycobacterial and immunosuppressive 
properties [4,5]
Bacteriostatic in vitro. MIC 90 <1.0 mg in vitro 
[28]. Apt concentrations attainable in vivo, 
particularly in macrophages [29,30].
Amoxicillin/clavulanic acid Amoxicillin (a penicillin) inhibits cell wall synthesis. Clavulinic acid is a beta-lactamase inhibitor β lactams in combination with beta lactamase 
inhibitors bactericidal in vitro [31,32,33].
Clarithromycin Inhibition of protein synthesis via binding to 50S ribosomal RNA as aminoacyl translocation reactions and 
the formation of initiation complexes are blocked [4,5].
Although in vitro antimycobacterial properties 
reported, data from animal and in vivo studies 
conflicting [34,35,36,37].
Rifabutin Activity is similar to that of rifampicin. Inhibits bacterial RNA synthesis by binding strongly to the β subunit 
of bacterial DNA-dependent RNA-polymerase [4].
May be useful against some isolates of MDR TB 
(resistant to RIF in vitro but sensitive to 
rifabutin) [38]. Effective in prevention and 
treatment of disseminated atypical 
mycobacterial infection in AIDS patients with 
CD4 counts <50 [4].
Thiacetazone Not clearly elucidated. In vivo and in vitro evidence of bacteriostatic 
activity. Cross-resistance frequently seen 
between thiacetazone and both INH and 
ethionamide [39,40].
Table 2: Classes of anti-TB drugs (Continued)Respiratory Research 2006, 7:118 http://respiratory-research.com/content/7/1/118
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periods. Poor patient compliance is the single most com-
mon reason for chemotherapy failure in TB [41]. To min-
imise toxicity and improve patients' compliance,
extensive progressive efforts have been made to develop
various implant-, microparticulate-, and various other car-
rier-based drug delivery systems to either target the site of
M. tuberculosis infection or reduce the dosing frequency,
which forms an important therapeutic strategy to improve
patient outcomes [47,48]. The systems under discussion
employ either biodegradable polymers or systems requir-
ing removal after use, and can release the drug either by
membrane or matrix-controlled diffusion.
Recent trends in controlled drug delivery have seen micro-
encapsulation of pharmaceutical substances in biodegrad-
able polymers as an emerging technology. Carrier or
delivery systems such as liposomes and microspheres
have been developed for the sustained delivery of anti-TB
drugs and have demonstrated better chemotherapeutic
efficacy when investigated in animal models (e.g. mice)
[47]. Anti-TB drugs have been successfully entrapped and
delivered in biodegradable polymers such as poly (DL-lac-
tide-co-glycolide) (PLG), which are biocompatible and
release drug in a controlled manner at therapeutic levels
[49]. Dutt and Khuller [50,51] have entrapped INH and
RIF in PLG polymers. When injected subcutaneously as a
single dose, the microparticles, having a diameter ranging
from 11.75 µm to 71.95 µm, provided sustained release of
drugs over 6–7 weeks when tested in mice [50]. The
authors previously observed that particles with a size
range >10 µm remained at the site of injection forming a
depot. The entrapped contents of the microparticles were
gradually released by diffusion through the polymeric
particles. Such depots can show release profiles extending
over several months culminating in degradation of the
entire polymeric device.
However, these formulations have to be injected either
subcutaneously or intravenously, and the pain and dis-
comfort associated with these routes of administration, in
general, is often not acceptable. Hence, there is a continu-
ous need to develop an oral drug delivery system that is
convenient for patients [41].
Amidst these concerns, Ain et al. [52] reported the phar-
macokinetics of PLG encapsulated anti-TB drugs; orally
administered either individually or in combination in
mice. A study conducted by Pandey et al. [48] reported the
formulation of three frontline anti-TB drugs, i.e. RIF, INH
and PYZ encapsulated in PLG nanoparticles. On oral
administration of drug-loaded nanoparticles to M. tuber-
culosis-infected mice at every 10th day, no tubercle bacilli
could be detected in the tissues after 5 oral doses of treat-
ment. Therefore, oral nanoparticle-based anti-TB drug
therapy can allow for a reduction in dosing frequency for
better management of TB. Prabakaran [41] developed an
osmotically regulated capsular multi-drug oral delivery
system comprising asymmetric membrane coating- and
dense semipermeable membrane coating-capsular sys-
tems for the simultaneous controlled administration of
RIF and INH for the treatment of TB. This was in an
attempt to reduce the problems associated with multi-
drug therapy. The modified asymmetric system provided
satisfactory sustained release of RIF and INH, with an ini-
tial burst release that may be sufficient to achieve mini-
mum effective concentration in blood. Thereafter, the
system provided the release of the drugs in a near zero
order rate – an ideal release profile for controlled drug
delivery. In turn, this would improve the safety profile of
the drugs and enhance the activity duration of drugs
exhibiting short half-lives. The once daily system is opti-
mal, and could potentially enhance patient compliance.
In addition to these combinations, the past several years
have seen the development of a number of RIF-only con-
trolled release formulations for the improvement of the
clinical efficacy of the drug and patient compliance [53-
62].
Further attempts to solve the problems inherent in multi-
drug therapy have included the development of biode-
gradable polymeric micro- or nanoparticulate carrier sys-
tems to target alveolar macrophages that harbour M.
tuberculosis [51,63-67]. In the case of pulmonary TB, deliv-
ering the drug directly to the site of infection through
inhalation of an aerosolised delivery system has the inher-
ent advantages of bypassing first-pass metabolism and
maintaining local therapeutically effective concentrations
with decreased systemic side effects [68]. Because M. tuber-
culosis is known to infect alveolar macrophages and affect
the pathogenesis of TB, there have been renewed interests
in targeting of anti-TB drugs to these cells. Despite the suc-
cess of these systems in targeting and providing sustained
release of anti-TB drugs to alveolar macrophages, the
methods used to generate particles in these studies vary in
their capability for the production of reproducible parti-
cles with the optimal size for inhalation therapy (i.e. <5
µm). Barrow et al. [64] formulated RIF-loaded micro-
spheres using the method of solvent evaporation, aiming
to maintain a size of 1-to 10-µm. Only the size distribu-
tions of two formulations were reported, being 3 to 4 µm,
and distribution demonstrated a Gaussian curve. Dutt and
Khuller [51] encapsulated INH and RIF into hardened
PLG microparticles by a double emulsification solvent
evaporation procedure, and these had a resultant volume
mean diameter of 11.75 µm for INH microparticles and
11.64  µm for RIF microparticles. These are currently
undergoing Phase I trials. Sharma et al. [66] incorporated
both INH and RIF into PLG microspheres using a combi-
nation of solvent extraction and evaporation, but theseRespiratory Research 2006, 7:118 http://respiratory-research.com/content/7/1/118
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particles had a mean diameter of 6.214 µm and only 38%
of the microspheres fell in the size range of 0.5–3 µm. Sua-
rez et al. [68,69] attained the airway delivery of RIF micro-
particles having volume median diameters of 2.76 ± 1.57
µm. O'Hara and Hickey [70] succeeded in obtaining RIF-
loaded PLG particles with median diameters by volume of
2.76 µm and 3.45 µm by spray drying and solvent evapo-
ration respectively. Zhou et al. [68] did achieve the formu-
lation of spherical microparticles between 1 and 3 µm in
diameter. The microparticles, prepared by the precipita-
tion with a compressed antisolvent process, were evalu-
ated for their potential in targeting an ionizable prodrug
of INH, isoniazid methanesulfonate (INHMS), for sus-
tained delivery of INH to alveolar macrophages.
Most recently Zahoor et al. [71,72] undertook pharma-
cokinetic and chemotherapeutic studies with aerosolised
alginate nanoparticles encapsulating INH, RIF and PZA
and RIF, INH, PYZ, ETB. The nanoparticles were prepared
by cation-induced gelification of alginate and were 235.5
± 0 nm in size, with drug encapsulation efficiencies of 70–
90% for INH and PZA and 80–90% for RIF and 88–95%
for EMB. The majority of particles (80.5%) were in the
respirable range, with a mass median aerodynamic diam-
eter of 1.1 ± 0.4 µm and geometric standard deviation of
1.71 ± 0.1 µm. The chemotherapeutic efficacy of three
doses of drug-loaded alginate nanoparticles nebulised 15
days apart was comparable with 45 daily doses of oral free
drugs. Thus, inhalable alginate nanoparticles could poten-
tially serve as an ideal carrier for the controlled release of
anti-TB drugs. Clinical trials are envisaged in the future for
evaluation of this system before use in humans.
Pandey and Khuller [73] evaluated the chemotherapeutic
potential of nebulised solid lipid nanoparticles (SLNs)
incorporating RIF, INH and PYZ against experimental TB.
SLNs are nanocrystalline suspensions in water, prepared
from lipids, which are solid at room temperature. The
SLNs, prepared by the emulsion solvent diffusion tech-
nique, possessed a favourable mass median aerodynamic
diameter suitable for bronchoalveolar drug delivery. Fol-
lowing a single nebulisation to guinea pigs, therapeutic
drug concentrations were maintained in the plasma for 5
days and in the organs for 7 days whereas free drugs were
cleared after 1–2 days. Vyas [74] formulated aerosolised
liposomes incorporating RIF via a cast-film method
employing egg phosphatidylcholine- and cholesterol-
based liposomes. Liposomes coated with alveolar macro-
phage-specific ligands demonstrated preferential accumu-
lation in alveolar macrophages, maintaining high
concentrations of RIF in the lungs even after 24 hours.
In another approach to solve the predicament of poor
patient compliance, depot-delivery of anti-TB drugs has
been investigated. Studies have demonstrated that a single
implant of INH in polylactic-co-glycolic acid (PLGA)
copolymer could ensure sustained levels of free INH for a
period of up to 8 weeks following implantation in rabbits
[49]. Gangadharam, et al. [74] have also investigated the
chemotherapy of TB in mice using single implants of INH
and PYZ. Such devices, however, inherently suffer from
the disadvantages of immobilisation at the implanatation
site and surgical requirements for implantation.
A number of the aforementioned developments in drug
delivery represent attractive options with significant
merit, and the pertinent points regarding each exemplary
investigation are summarised in Table 3; however, the
need to develop an oral drug delivery system with
improved patient acceptance is affirmed by the acceler-
ated pace of oral drug delivery system development fos-
tered by the need to deliver medications to patients more
efficiently and with fewer side effects, especially in devel-
oping countries where controlled-delivery implants and
injectables could be too expensive.
Rifampicin bioavailability concerns
The WHO and the International Union Against Tubercu-
losis and Lung Disease (IUATLD) encourage use of Fixed
Dose Combination (FDC) formulations – this evolved
from the fact that TB always requires multi-drug treatment
[76]. Patients should thus be given FDC adjusted for body
weight whenever self-administration of anti-TB drugs is
permitted [3]. A FDC – which is a combination of two or
more first-line anti-TB drugs in a single formulation at a
fixed proportion – prevents monotherapy; and it is
expected that this will reduce the emergence of MDR TB;
simplify treatment, and thus minimize prescription error
and increase patient and doctor compliance; simplify
drug stock management, shipping and distribution; and
reduce the risk of misuse of RIF for conditions other than
TB [10].
Of dire concern, however, is the issue of unacceptable RIF
bioavailability in a number of FDC anti-TB formulations
[77,78]. The decomposition of RIF has varied from 8.5 to
50% in the acidic environment of the stomach in the time
range corresponding to the gastric residence time for most
dosage forms in humans (≈15 minutes to 105 ± 45 min-
utes) [79,80]. However, the gastric-emptying time for
some single-unit dosage forms may reach 6 hours [81].
The use of substandard FDC will ultimately result in drug
resistant TB and treatment failure [77]. The factors pro-
posed for this variation in the bioavailability of RIF from
different FDC formulations include the particle size and
crystalline form of the drug, manufacturing process and
the excipients employed [82,83]. The effect of these fac-
tors, however, has not been convincingly explained in pre-
vious studies. RIF is known to undergo hydrolysis in
acidic medium to the insoluble 3-formyl rifamycin SV (3R
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Table 3: Synopsis of Novel Anti-TB Drug Delivery Systems
Drug Delivery System and 
Polymer Employed
ROA Preparatory Methods Characterisation Studies and System Suitability Reference
INH Porous, non-porous 
and hardened 
microparticles 
employing PLG
SC injection Double emulsification 
solvent evaporation
Size: Mean volume diameters were: 62.11 µm, 71.95 µm and 11.75 µm for porous, non-
porous and hardened microparticles, respectively.
In vitro studies: Sustained release of INH up to 6 days from non-porous microparticles. 
Porous microparticles released INH over 3 days.
Hardened PLG microparticles sustained release of INH for up to 7 weeks
In vivodisposition studies (in mice): Porous and non-porous microparticles released INH in 
plasma for up to 2 days. Hardened PLG microparticles sustained release of INH for up to 7 
weeks. Concentrations of INH obtained were higher than the MIC of INH.
[50]
RIF, INH, 
PYZ, ETB
Microparticles 
employing PLG
Oral, singly or 
in combi-nation
Double emulsification 
solvent evaporation
DEE: 8–10% for PZA; 10–11% for INH and 12–18% for RIF.
Size: Diameters were 1.11 µm for INH, 1.40 µm for RIF and 2.20 µm for PZA microparticles.
In vitro studies: Entrapped drugs were released in a sustained manner. In the intestinal fluid 
drug release was obtained for up to 20 days
In vivo studies: Entrapped drugs remained in circulation up to 72 h as compared to free drugs 
(eliminated within 24 h). Level of PLG encapsulated INH was found to be higher than its MIC 
value (0.1 µg/ml).
Pharmacokinetic analysis (PLG encapsulated drugs and free drugs): Increased Cmax; AUCo-α; t1/2 
(a) and t1/2 (e) when drug were given entrapped in PLG microparticles indicated the potential 
of PLG for effective treatment of TB
[52]
RIF, INH, PYZ Nanoparticles 
employing PLG
Oral Multiple emulsion 
technique
Size: Majority (>80%) in the size range of 186–290 nm, polydispersity index of 0.38 ± 0.04
DEE: 56.9 ± 2.7% for RIF, 66.3 ± 5.8% for INH and 68 ± 5.6% for PZA.
Drug loading: 570 to 680 mg drug per gram of polymer.
In vitro studies: drug release profile in PBS showed an initial (up to 48 h) burst release 
followed by a negligible release of either drug up to 6 weeks.
In vivo studies (experimental infection and chemotherapy): following oral administration of drug-
loaded nanoparticles to M. tuberculosis-infected mice at every 10th day – no tubercle bacilli 
could be detected in the tissues after 5 oral doses of treatment
[48]
RIF, INH Osmotically regulated 
capsular multi-drug 
oral delivery system 
employing HPMC and 
NaCMC
Oral Phase inversion process 
– precipitation of 
membrane structure on 
a stainless steel mould 
pin
SEM: porous structure of the membranes was evident.
In vitro studies: sustained release of RIF and INH, with initial burst release, which may be 
sufficient to achieve MIC in blood. Thereafter, the system sustained the release of the drugs 
in a near zero order rate
In vitro release kinetics: first order kinetics. Statistical analysis of release rate data – modified 
asymmetric system the preferred system.
[41]
INH, RIF Microparticles 
employing PLG
SC, Inhaled Double emulsification 
solvent evaporation
Size: Volume mean diameters of 11.75 µm (INH-loaded) and 11.64 µm (RIF-loaded)
DEE: 10–11% (INH-loaded) and 12–14% (RIF-loaded)
In vivo-combination drug disposition studies and experimental infection and chemotherapy 
studies: single dose of PLG microparticles – sustained release of INH and RIF for up to 7 and 
6 weeks, respectively. Free drugs (in combination) injected in the same doses were 
detectable in vivo up to 24 h only. One dose of PLG microparticles cleared bacteria more 
effectively from lungs and liver in experimental murine model of TB (compared with a daily 
administration of the free drugs) Phase I trials
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RIF Microspheres 
employing PLG
Inhaled/aerosol Solvent evaporation Size: reported for 2 formulations – 3 to 4 µm, and distribution demonstrated a Gaussian 
curve.
In vitro studies: best in vitro release patterns, resulted in 21 and 12% cumulative in vitro drug 
release, respectively, after 6 days
Release in monocytic cell lines (murine J774 and the human Mono Mac 6): Bioassay assessment 
of cell culture supernatants from monocyte cell lines – release of RIF during a 7-day 
experimental period. Treatment of M. tuberculosis H37Rv-infected monocyte cell lines with 
RIF-loaded microspheres resulted in a significant decrease in numbers of CFU at 7 days 
following initial infection
[64]
INH, RIF Microspheres 
employing PLG
Inhaled Combination of solvent 
extraction and 
evaporation
Size: mean diameter of 6.214 µm and only 38% of the microspheres fell in the size range of 
0.5–3 µm
In vivo studies: Microspheres were tested for uptake by murine macrophages in culture and 
resultant intracellular drug concentrations. The extent of microparticle delivery in vivo was 
examined by flow-cytometry. Drug concentrations (blood and alveolar macrophages) 
estimated after oral, vascular, intratracheal, and inhalation administration. Large numbers of 
particles delivered to the bronchiopulmonary system through a 2 min exposure to fluidized 
particles. The intracellular drug concentrations resulting from vascular delivery of soluble 
drugs were lower than those resulting from particle inhalation.
[66]
RIF Microparticles 
employing PLGA
Inhaled Spray drying Size: Volume median diameters (VMD) and geometric standard deviations (S.D.) were [VMD 
(µm)/geometric S.D.]: RIF-PLGA, 2.76/1.57; PLGA, 2.87/1.45; and RIF alone, 3.83/1.75.
In vivo studies: Alveolar macrophage M. tuberculosis(H37Rv)-infected guinea pig model was 
used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or 
nebulisation RIF-PLGA microspheres. Animals treated with single and double doses of RIF-
PLGA microspheres – reduced numbers of viable bacteria, inflammation and lung damage 
compared with RIF-only treated animals 28 days post-infection. Two doses of RIF-PLGA – 
reduced splenic enlargement.
[69]
RIF Microparticles 
employing PLGA
Inhaled Solvent evaporation 
and spray drying
Morphology: Spray dried RIF-loaded PLGA microparticles – shriveled morphology, spherical 
particles produced by solvent evaporation.
Size: Median diameters by volume were 3.45 µm (solvent evaporation) and 2.76 µm (spray 
dried)
DEE: 20% (solvent evaporation) and 30% (spray dried)
Particles are being evaluated in an animal model of TB.
[70]
Ionizable 
prodrug of 
INH, INHMS
Spherical 
microparticles 
employing PLA
Inhaled Precipitation with a 
compressed antisolvent 
process
Drug loading efficiency: 93 to 152%
Size: Aerodynamic diameters ranged from 1 to 3 µm
In vitro studies: Release profiles displayed two phases of drug release that were characterised 
by an initial burst effect, followed by a period of slower release
In vivo studies (drug accumulation in cultured rat alveolar macrophages): Liquid chromatographic 
tandem mass spectrometric (LC-MS/MS) assay developed detected high level of INH in 
NR8383 (rat AM cell line) following exposure to drug-loaded microparticles. Compared INH 
levels in lavaged bronchoalveolar macrophages by LC-MS/MS after Sprague-Dawley rats 
administered either INHMS in PLA microparticles by intra-tracheal instillation or INH 
solution by gavage or intra-tracheal instillation – sustained delivery of INH to alveolar 
macrophages.
Reduction in the blood levels of acetylisoniazid (AcINH), a major and potential toxic 
metabolite of INH.
[68]
Table 3: Synopsis of Novel Anti-TB Drug Delivery Systems (Continued)R
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INH, RIF, PZA 
and RIF, INH, 
PYZ, ETB
Nanoparticles 
employing alginate
Inhaled Cation-induced 
gelification of alginate
Size: 235.5 ± 0 nm in size, with majority of particles (80.5%) were in the respirable range, 
with mass median aerodynamic diameter of 1.1 ± 0.4 µm and geometric standard deviation 
of 1.71 ± 0.1 µm.
DEE: 70–90% for INH and PZA, 80–90% for RIF and 88–95% for ETB.
In vivo studies (disposition studies and chemotherapeutic studies): The formulation was orally 
administered to mice at two dose levels. A comparison was made in mice receiving free 
drugs at equivalent doses. Relative bioavailabilities of drugs encapsulated in alginate 
nanoparticles significantly higher compared with oral free drugs. Drug levels were maintained 
at or above the MIC90 post nebulisation until Day 15 in organs (lungs, liver and spleen) after 
administration of encapsulated drugs, whilst free drugs stayed at or above the MIC90 up to 
Day 1 only irrespective of dose.
Clinical trials envisaged in the future
[71,72]
RIF, INH and 
PYZ
Nebulised SLNs 
prepared from 
nanocrystalline lipid 
suspensions in water
Inhaled Emulsion solvent 
diffusion technique
Size: favourable mass median aerodynamic diameter suitable for bronchoalveolar drug 
delivery
In vivo studies: Therapeutic experimental TB drug concentrations were maintained in the 
plasma for 5 days and in the organs for 7 days whereas free drugs were cleared by 1–2 days
[73]
RIF Aerosolised liposomes 
formulated using Egg 
PC-and Chol-based 
liposomes
Inhaled Neutral liposomes 
were prepared by cast 
film method
Modification: Imparted negative charge (DCP) or by coating them with alveolar macrophage-
specific ligands (MBSA and O-SAP).
Size: neutral and negatively charged liposomes composed of PC:Chol:DCP had average 
vesicle size of 2.32 ± 0.48 µm and 2.50 ± 0.54 µm, respectively. MBSA-coated liposomes size: 
3.64 ± 0.65 µm, O-SAP-coated vesicles size: 3.85 ± 0.59 µm.
DEE: 47.4 ± 2.7%
In vivo studies: Percent viability of Mycobacterium smegmatis inside macrophages (in vitro) after 
administration of drug (in vivo) was 7–11% (ligand-anchored liposomal aerosols), 45.7 and 
31.6% in case of plain drug and plain neutral liposomal aerosol (based on PC:Chol)-treated 
macrophages. Preferential accumulation of MBSA- and O-SAP-coated formulations in alveolar 
macrophages. Drug was estimated in the lung in high concentration (even after 24 h).
[74]
INH Implant prepared from 
PLGA
Depot PLGA polymer rods In vivo studies: Rods implanted in the back of rabbits under anaesthesia. Concentrations of 
INH and acetylisoniazid in serum and urine determined by HPLC. Concentrations of INH ≥ 
0.2 µg/ml were found both in serum and urine up to 63 days after implant. Urine specimen 
obtained at 6 weeks after implant inhibited the growth of M. tuberculosis in vitro measured by 
the radiometric (Bactec) method.
[49]
INH, PYZ Single implants 
prepared from PLGA
Depot Depot drug preparation In vivo studies: 3 times the daily dose of PYZ contained in single PLGA polymer implant – no 
burst levels of the drug evident after administration – sustained levels up to 54 days. 
Chemotherapeutic activity (investigated in mice) of the single PLGA polymer implants similar 
to standard oral treatment with the two drugs given daily for 8 weeks, determined by 
mortality and CFU counts of tubercle bacilli from lungs and spleen.
[75]
Chol = cholesterol, DCP = dicetylphosphate, DEE = drug entrapment efficiency, HPLC = high performance liquid chromatography, HPMC = hydroxypropylmethylcellulose, MIC = minimum 
inhibitory concentration, NaCMC = sodium carboxymethylcellulose, PBS = phosphate-buffered saline, PC = phosphatidylcholine, MBSA = maleylated bovine serum albumin, and O-SAP = O-
steroyl amylopectin, ROA = route of administration, SC = subcutaneous, SLNs = solid lipid nanoparticles
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FRSV). INH accelerates degradation of RIF into this poorly
absorbed derivative (3 FRSV) in the acidic environment of
the stomach via reversible formation of the isonicotinyl
hydrazone of 3-FRSV with INH [80,84,85]. Shishoo et al.
[80] has indicated that RIF in the presence of INH as a
FDC, may undergo greater decomposition in the acidic
conditions of the stomach, as compared to when RIF is
administered (orally) alone. Thus, less RIF will be availa-
ble for absorption from FDCs as compared to RIF admin-
istered as a separate formulation. This will be reflected in
the poor bioavailability from the former formulation.
There is thus an urgent need to modify or segregate the
FDC formulation in such a way that RIF and INH are not
released simultaneously in the stomach. Alternatively
both drugs need to be administered separately after an
interval corresponding to average gastric residence time,
which is somewhat unpredictable due to high intra- and
inter-subject variability [79,80,88].
Fairly recently, Chen [42] proposed a mechanism for this
apparent degradation of RIF. 3-FRSV and INH could pos-
sibly undergo Schiff's reaction to form a complex (Figure
4(a)). The carbonyl groups and amine groups may rear-
range to yield an iminium ion. The C-4 hydroxy group
enhances the complex formation by possibly forming a
hydrogen bond with the hydrogen atom attached to the
nitrogen. This is a basic requirement of the Schiff's reac-
tion. In addition, carboxylic acids and alcohols can also
undergo carbonyl condensation reactions [89]. INH could
react with RIF in this manner, which could account for the
instability of RIF when present together with INH (Figure
4(b)). This interaction could also occur between RIF and
PYZ, however, it has frequently been observed that INH
caused further RIF stability reduction compared to PYZ.
The reason for this could be due to the fact that the car-
boxylic acids and alcohol further undergo Fischer's esteri-
fication [89]. The hydroxyl groups of RIF are readily able
Proposed mechanisms for interaction between RIF and INH Figure 4
Proposed mechanisms for interaction between RIF and INH: (a) Schiff's Reaction of RIF and INH, (b) Carbonyl Condensation 
of RIF and INH, (c) Fischer's Esterification Reaction between RIF and INH.
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to react with the aqueous carboxylic acid degradants
yielded by INH and PYZ to form an ester (Figure 4(c)).
However, as PYZ lacks the electron-withdrawing group,
such as the secondary nitrogen found on the hydrazide
group of INH, there is less tendency for this reaction to be
expected between PYZ and RIF.
Permeability studies have demonstrated that RIF is well
absorbed from the stomach due to its solubility, which
has been shown to be maximal between pH 1–2. INH,
although demonstrating solubility in the gastric environ-
ment, is comparatively well absorbed from all three seg-
ments of the small intestine. RIF and INH thus exhibit
regional specific permeability, and the bioavailability
problems associated with RIF could be overcome by
developing an FDC in which the delivery of the two drugs
is segregated, with RIF released in the stomach and INH in
the small intestine [90]. A FDC multiparticulate oral sys-
tem, which boasts ease of manufacture and directly
attacks RIF bioavailability concerns and poor patient com-
pliance with existing FDC anti-TB formulations, is yet to
be globally developed.
The rationale for the development of a novel 
fixed dose combination anti-TB drug delivery 
system
Drug delivery, which takes into consideration the carrier,
the route and the target, has evolved into a strategy of
processes or devices designed to enhance the efficacy of
therapeutic agents through modified or controlled
release. This may involve enhanced bioavailability,
improved therapeutic index, or improved patient accept-
ance or compliance. Drug delivery has been defined by
Flynn [91] as 'the use of whatever means possible, be it
chemical, physicochemical or mechanical, to regulate a
drug's access rate to the body's central compartment, or in
some cases, directly to the involved tissues'. The underly-
ing principle that drug delivery technology can bring both
therapeutic and commercial value to health care products
has been widely accepted. This has created an intense
need for presenting 'old' drugs, such as those encom-
passed in the anti-TB regimen, in new forms utilising
novel modes of delivery and dosage forms [92].
Patient failure to take the prescribed medications at the
required intervals results in significant morbidity and
mortality. The need for research into an oral anti-TB drug
delivery system is thus warranted as the efficacy of the cur-
rent regimen may be improved if the delivery rate, biodeg-
radation, and site-specific targeting can be predicted,
monitored, and controlled. From a financial and a global
health care perspective, finding new ways to administer
the anti-TB drugs in oral form and delivering the multiple-
dose, long-term therapy in inexpensive, potent, forms
with improved bioavailability is needed. The provision of
an administration method, embodied by a dosage form
that addresses FDC bioavailability concerns, that will
allow patients to safely treat themselves and enhance their
compliance with the anti-TB regimen is a significant
health care development, particularly in developing coun-
tries where access to doctors, clean syringes, sterile nee-
dles, and sophisticated treatments are few and far
between.
As mentioned, the major route of drug administration is
through the oral cavity. This route provides the greatest
comfort and convenience of dosing. In addition to avoid-
ing the patient discomfort associated with the parenteral
route, the accidental overdosing of the drug can be cor-
rected by withdrawing the unabsorbed drug from the
stomach. An anti-TB dosage form that can be orally
administered once daily would be optimal for patient
compliance [41].
In addressing oral bioavailabiliity concerns, chemical
modification or prodrug formation may well be success-
fully implemented to alter the pharmacokinetics of RIF
and INH. Prodrug strategies have successfully improved
the oral bioavailability of numerous compounds. In many
cases, this involves masking a polar group by esterification
to increase lipophilicity and enhance the extent of absorp-
tion from the gastrointestinal tract. After absorption, the
ester is enzymatically hydrolysed to release the parent
drug.
RIF was developed in the Dow-Lepetit Research Laborato-
ries (Milan, Italy) as part of an extensive program of chem-
ical modification of the rifamycins, the natural
metabolites of Nocardia mediterranei as the hydrazone
with N-amino-N'-methylpiperazine that was the most
active in the oral treatment of infections in animals and,
after successful clinical trials, was introduced into thera-
peutic use in 1968 [93]. To date, no form of RIF has been
widely clinically applied that significantly improves on its
oral bioavailability. There is little solubility advantage
associated with polymorphic forms, which is inconse-
quential from a clinical and regulatory point of view [94].
A piperine composition for the improvement of gastroin-
testinal absorption and systemic utilisation of nutrients
and nutritional supplements comprising an extract from
the fruit of Piper containing a minimum of 98% of pure
alkaloid piperine, has been added to multi-drug formula-
tions for the treatment of TB and leprosy. A formulation,
containing RIF, INH and PYZ and the said composition,
has been tested in human volunteers (Indian Patent No.
1232/DEL/89). In the majority of cases, the comparative
levels and peak concentration of the drugs in the presence
of piperine were higher. The applicability of these results
to bioavailability enhancement, which aims to lower dos-
age levels and shorten the treatment course, is apparent,Respiratory Research 2006, 7:118 http://respiratory-research.com/content/7/1/118
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but presently cost prohibitive in developing countries
[95].
INH was synthesised in 1912 from ethyl isonicotinate and
hydrazine by Meyer and Malley as part of their doctoral
work in Prague. In 1945, its anti-TB properties were eluci-
dated when nicotinamide was discovered to have anti-TB
effects. Being a pro-drug itself, activated through endog-
enous mycobacterial catalysis, various additional chemi-
cal miodifications have been invesigated to alter INH
pharmacokinetics. Gianolla et al. [96] attached various
acyl groups to the amine (-NH2) function of INH for
improved lipophilicity and afforded good yields in pro-
drugs, which were characterised by spectroscopic and ana-
lytical methods. Crooks et al. [97] proposed the fabrica-
tion of an INH prodrug through the formation of covalent
conjugates of INH with mono-di- and polyoxaalkanoic or
thiaalkanoic acids. The conjugation is purported to pro-
vide covalent compounds having a chemotherapeutic
effect, with enhanced permeation of biological mem-
branes, which remain intact until enzymatically cleaved.
As reported, Zhou et al. [68] developed an ionizable pro-
drug of INH, INHMS, for sustained delivery of INH to
alveolar macrophages. The charged prodrug was ion-
paired with two different hydrophobic cations: tetrap-
entylammonium-and tetraheptylammonium-bromide.
The prodrug required loading into microparticles for real-
isation of the targeted sustained effect.
Prodrug formation is clinically relevant in altering in vivo
disposition kinetics and in attaining sustained release, but
developments have not necessarily addressed the deleteri-
ous RIF-INH interaction upon oral administration.
Shishoo et al. [80] have promoted the need for the devel-
opment of a stable formulation containing the RIF-INH
combination for differentiated GI release and have sug-
gested enteric-coated tablets or alternative multilayered
dosage forms.
In developing an oral modified-release system, cogni-
sance must be taken of the increase in popularity of mul-
tiparticulate solid dosage forms (e.g. microparticles,
nanoparticles, beads, pellets, granules) in the area of oral
controlled drug delivery [98]. Formulation of an anti-TB
dosage form as an oral multiparticulate drug-delivery sys-
tem would furnish many biopharmaceutical advantages
when compared with solid single-unit dosage forms in
terms of a more even and predictable distribution and
transportation in the gastrointestinal tract that is fairly
independent of the nutritional state, predictable gastroin-
testinal transit time, less localised gastrointestinal distur-
bances and greater product safety; as well as having an
application in the improvement of patient compliance. In
view of the many benefits offered by multiple unit dosage
forms, it is speculated that such systems are particularly
useful for site-specific targeting within the gastrointestinal
tract [99,100].
In order to manufacture an oral system as cheaply and
efficiently as possible in developing countries, intrinsic
drug delivery principles may be implemented, employing
readily available polymeric and other formulatory excipi-
ents to segregate the delivery of the pure drugs. Currently
under investigation in our laboratories is the develop-
ment of a pharmaceutical RIF-INH multiparticulate com-
position intended for facilitated oral administration that
ensures differentiated release of RIF and INH in the gas-
trointestinal tract. Agrawal et al. [94] have indicated that
RIF release in the acidic medium is critical for RIF bioa-
vailability. There is thus the requisite to deliver RIF in a
highly available form that will be readily absorbed from
the gastric environment. The intended delivery system
exemplifies the requirements of small intestinal INH
delivery and immediate gastric availability of RIF.
Conclusion
The current novel drug delivery approaches reviewed all
demonstrate significant merit, however, a FDC oral multi-
particulate system, which is cheap to manufacture and
directly addresses issues of unacceptable RIF bioavailabil-
ity in FDC anti-TB formulations, is yet to be globally
developed The fabrication of a polymeric once-daily oral
multiparticulate FDC of the principal anti-TB drugs,
which attains segregated delivery of RIF and INH for
improved RIF bioavailability, could be a step in the right
direction in addressing issues of treatment failure due to
patient non-compliance, the consequences of which are
devastating.
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